Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,048 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03051464 | Randomizing Two Radiotherapy Boost Options to Avoid Rectal Cancer Surgery(MORPHEUS) | recruiting | Phase 2 / Phase 3 | 131 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 2 | Jun 30, 2026 | clinicaltrials |
| NCT06905002 | Enhancing the Patient Journey to Clinical Trial Enrolment With Navigation to Optimize Accrual | recruiting | N/A | 300 | Windsor Regional HospitalOTHER | 1 | Jun 30, 2026 |
| clinicaltrials |
| NCT03246802 | Partial Prostate Salvage High Dose Rate Brachytherapy(SalvageHDR) | recruiting | N/A | 30 | British Columbia Cancer AgencyOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT05508464 | Ablative Radiotherapy to Restrain Every Metastasis Safely Treatable (ARREST-2): A Randomized Phase II/III Trial(ARREST2) | recruiting | N/A | 138 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 2 | Jun 29, 2026 | clinicaltrials |
| NCT06333899 | Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion | recruiting | Early Phase 1 | 15 | Nationwide Children's HospitalOTHER | 6 | Jun 29, 2026 | clinicaltrials |
| NCT07049276 | The Multicentre Selective Lymphadenectomy Trial - 3(MSLT-3) | recruiting | N/A | 1,500 | Melanoma Institute AustraliaOTHER | 6 | Jun 29, 2026 | clinicaltrials |
| NCT04614103 | Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer | recruiting | Phase 2 | 170 | Iovance Biotherapeutics, Inc.INDUSTRY | 12 | Jun 26, 2026 | clinicaltrials |
| NCT07648160 | Contrast-enhanced CBCT With C-arm HyperSight Technology(IV-CBCT) | recruiting | N/A | 20 | University Health Network, TorontoOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT06220864 | SNV1521 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 400 | Synnovation Therapeutics, Inc.INDUSTRY | 7 | Jun 25, 2026 | clinicaltrials |
| NCT06431594 | A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1) | recruiting | Phase 1 | 675 | GlaxoSmithKlineINDUSTRY | 15 | Jun 25, 2026 | clinicaltrials |
| NCT04641247 | A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study | recruiting | Phase 2 | 37 | GlaxoSmithKlineINDUSTRY | 8 | Jun 24, 2026 | clinicaltrials |
| NCT05676099 | TSC Biosample Repository and Natural History Database | recruiting | — | 5,000 | National Tuberous Sclerosis AssociationOTHER | 2 | Jun 24, 2026 | clinicaltrials |
| NCT06455384 | The Genetics Navigator: Evaluating a Digital Platform for Genomics Health Services | recruiting | N/A | 170 | Unity Health TorontoOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT06835725 | Phase II Randomized Trial of 2 Versus 5 Fraction Prostate Stereotactic Ablative Radiotherapy for Intermediate Risk Prostate Cancer(ADAPT-25) | recruiting | Phase 2 | 100 | British Columbia Cancer AgencyOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07387263 | Mainstreaming Genetics: Evaluation of a Digital Application to Scale and Spread Oncologist-initiated Genetic Testing | recruiting | N/A | 180 | Unity Health TorontoOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT00196742 | Fabry Disease Registry & Pregnancy Sub-registry | recruiting | — | 9,000 | Genzyme, a Sanofi CompanyINDUSTRY | 44 | Jun 23, 2026 | clinicaltrials |
| NCT03179540 | Non-operative Management for Locally Advanced Rectal Cancer(NOM) | recruiting | N/A | 90 | Mount Sinai Hospital, CanadaOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT03818412 | Circulating Tumor DNA in Soft Tissue Sarcoma | recruiting | N/A | 40 | University Health Network, TorontoOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT04510636 | Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma | recruiting | Phase 2 | 40 | University Health Network, TorontoOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT06813079 | Using Tumor Models to Determine Treatments | recruiting | Phase 2 | 25 | University Health Network, TorontoOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07048743 | Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Caregivers of Patients With Advanced Cancer(PEARL-C1) | recruiting | Phase 2 | 15 | University Health Network, TorontoOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT00913939 | High-Dose-Rate Brachytherapy | recruiting | N/A | 500 | University Health Network, TorontoOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT05434234 | A Study of YL201 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 312 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 6 | Jun 22, 2026 | clinicaltrials |
| NCT05696626 | Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation(ELAINEIII) | recruiting | Phase 3 | 600 | LeonaBioINDUSTRY | 17 | Jun 22, 2026 | clinicaltrials |
| NCT05700149 | Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma | recruiting | — | 300 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 15 | Jun 22, 2026 | clinicaltrials |
| NCT06104566 | Global Trial in APG2575 for Patients With CLL/SLL | recruiting | Phase 3 | 400 | Ascentage Pharma Group Inc.INDUSTRY | 19 | Jun 18, 2026 | clinicaltrials |
| NCT06456580 | A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG) | recruiting | Phase 3 | 180 | Vor BiopharmaINDUSTRY | 14 | Jun 18, 2026 | clinicaltrials |
| NCT07215585 | AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL(SOUNDTRACK-D2) | recruiting | Phase 3 | 420 | AstraZenecaINDUSTRY | 11 | Jun 18, 2026 | clinicaltrials |
| NCT01120353 | Childhood Cancer Survivor Study | recruiting | — | 50,000 | St. Jude Children's Research HospitalOTHER | 2 | Jun 17, 2026 | clinicaltrials |
| NCT07261631 | Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors | recruiting | Phase 1 | 180 | Novartis PharmaceuticalsINDUSTRY | 6 | Jun 17, 2026 | clinicaltrials |
| NCT05208047 | (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors | recruiting | Phase 3 | 482 | Cogent Biosciences, Inc.INDUSTRY | 22 | Jun 16, 2026 | clinicaltrials |
| NCT05491525 | Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC(KANGUROO) | recruiting | Phase 2 / Phase 3 | 71 | Urovant Sciences GmbHINDUSTRY | 16 | Jun 15, 2026 | clinicaltrials |
| NCT06253130 | A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 156 | Eikon TherapeuticsINDUSTRY | 8 | Jun 15, 2026 | clinicaltrials |
| NCT06930521 | JUdicious Surveillance for Trastuzumab Induced Cardiotoxicity in the First Year(JUSTIFY) | recruiting | N/A | 300 | Women's College HospitalOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07456605 | Study of the Safety and Usefulness of Liposomal Curcumin in Multiple Myeloma | recruiting | Phase 1 | 20 | University Health Network, TorontoOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05754840 | CANnabinoids in Pediatric ONCology(CAN-PONC) | recruiting | Phase 1 / Phase 2 | 60 | University of ManitobaOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT06363266 | A SMART Design to Optimize the Delivery of TEMPO for Men With Prostate Cancer and Their Caregivers | recruiting | N/A | 376 | St. Mary's Research Center, CanadaOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT06451445 | A Pan-Canadian, Investigator Initiated Clinical Trial With Focal IRE Directed to Intermediate-Risk Prostate Cancer(WIRED) | recruiting | N/A | 100 | University Health Network, TorontoOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT04243720 | Immune Resistance Interrogation Study(IRIS) | recruiting | — | 100 | University Health Network, TorontoOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT04560036 | FAZA PETMRI Gastro-Oesophageal Study | recruiting | N/A | 40 | University Health Network, TorontoOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT05403177 | Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)(MOHCCN-O) | recruiting | — | 500 | University Health Network, TorontoOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT06050707 | MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach(MAESTRO) | recruiting | Phase 2 | 80 | University Health Network, TorontoOTHER | 3 | Jun 10, 2026 | clinicaltrials |
| NCT02821013 | Duration of Anti-PD-1 Therapy in Metastatic Melanoma(STOP-GAP) | recruiting | Phase 3 | 614 | Canadian Cancer Trials GroupNETWORK | 2 | Jun 9, 2026 | clinicaltrials |
| NCT03550391 | Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases | recruiting | Phase 3 | 206 | Canadian Cancer Trials GroupNETWORK | 2 | Jun 9, 2026 | clinicaltrials |
| NCT04665388 | LANDscape MApping of Epitopes and T Cell Receptors for Selected Cancers(LANDMARC) | recruiting | — | 105 | University Health Network, TorontoOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT05254782 | Using ctDNA to Detect Minimal Residual Disease After Lung Cancer Resection | recruiting | — | 360 | University Health Network, TorontoOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT05963217 | Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL | recruiting | Phase 1 | 19 | University Health Network, TorontoOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT06167785 | A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T(ZeTA) | recruiting | Phase 2 | 76 | University Health Network, TorontoOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT03947385 | Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions | recruiting | Phase 1 / Phase 2 | 336 | IDEAYA BiosciencesINDUSTRY | 3 | Jun 8, 2026 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials